Literature DB >> 12640315

Human leukocyte antigens DR and AB and kidney retransplantation.

John S Thompson1, Leroy R Thacker, Gopal Krishnan.   

Abstract

BACKGROUND: Although class II human leukocyte antigen (HLA) DR mismatching has been shown to demonstrate a significant effect on kidney regraft survival, it has not generally been clinically emphasized.
METHODS: We examined 2,574 kidney retransplants performed in Southeastern Organ Procurement Foundation centers between January 1988 and December 1997 in which there was ABDR typing on both donor and recipient and pretransplant panel reactive antibody (PRA) data.
RESULTS: Cox regression of multiple variables demonstrated that the most important risk factors in descending order were DR mismatching, non-white recipient, female donor, PRA as a continuous variable, and cold ischemia time. Although DR mismatching demonstrated a significant effect in white recipients, the impact was much greater in non-white recipients. In both groups, zero to four AB mismatches demonstrated no significant effect on regraft survival if DR was matched and only a minimal effect when DR was mismatched. The discrepancy of these findings with reports that demonstrate a stepwise decrease in regraft survival on the basis of the total zero to six ABDR mismatches was explained by the fact that the zero to six ABDR mismatches are a combination of AB mismatches with little effect and DR mismatches with a major effect. Regraft survival decreased progressively in association with increasing PRA.
CONCLUSIONS: DR matching is critically important in kidney retransplantation. There was no significant difference in survival of zero ABDR mismatched retransplants compared with one to four AB and zero DR mismatched retransplants. On the other hand, kidney graft survival of all one to four AB and zero DR mismatches exceeded that of one or two DR mismatched retransplants. We propose that the association of decreasing regraft survival with increasing PRA reflects undetected sensitization to class II, and possibly class I, antigens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12640315     DOI: 10.1097/01.TP.0000048376.79803.C1

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.

Authors:  Rene J Duquesnoy; Yehia Awadalla; Jon Lomago; Larry Jelinek; Judy Howe; Dwayne Zern; Betty Hunter; Joan Martell; Alin Girnita; Adriana Zeevi
Journal:  Transpl Immunol       Date:  2007-10-30       Impact factor: 1.708

2.  An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival.

Authors:  Juan C Scornik; Jonathan S Bromberg; Douglas J Norman; Mayank Bhanderi; Matthew Gitlin; Jeffrey Petersen
Journal:  BMC Nephrol       Date:  2013-10-10       Impact factor: 2.388

3.  Novel surgical techniques, regenerative medicine, tissue engineering and innovative immunosuppression in kidney transplantation.

Authors:  Maciej Nowacki; Łukasz Nazarewski; Tomasz Kloskowski; Dominik Tyloch; Marta Pokrywczyńska; Katarzyna Pietkun; Arkadiusz Jundziłł; Janusz Tyloch; Samy L Habib; Tomasz Drewa
Journal:  Arch Med Sci       Date:  2016-08-25       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.